CTVA · Q3 2025 Earnings

Bullish

Corteva

Reported November 4, 2025

30-second summary

Corteva posted Q3 revenue of $2.62B (+12.5% YoY) on 11% organic growth, with Seed +32.7% and Crop Protection +4% driving a second consecutive guidance raise. Management lifted FY25 operating EPS to $3.25–$3.45 (from $3.00–$3.20), EBITDA to $3.80B–$3.90B (from $3.75B–$3.85B), and bumped FY25 margin expansion expectation to ~165bps (from ~150bps) — and pre-announced FY26 EBITDA around $4.1B (mid-single-digit growth). The catch worth flagging: last quarter's $450M net cost improvement target was quietly retired and replaced with "over $600M in controllable benefits," a broader and less directly comparable framing.

Headline numbers

EPS

Q3 FY2025

$-0.23

Revenue

Q3 FY2025

$2.62B

+12.5% YoY

Gross margin

Q3 FY2025

37.2%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$2.62B	+12.5%	$6.46B	-59.4%
EPS	$-0.23	—	$2.20	-110.5%
Gross margin	37.2%	—	54.6%	-1738bps

Guidance

Full-year FY2025 EPS and EBITDA guidance raised; margin expansion expectations increased by 15 bps; FCF reaffirmed but cost improvement target replaced with broader 'controllable benefits' language.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Operating EPS	FY2025	$3.00 to $3.20	$3.25 to $3.45	+$0.25 to +$0.25 at midpoints (3.1 → 3.35); +28% YoY growth at midpoint vs +21% prior	Raised
Operating EBITDA	FY2025	$3.75 billion to $3.85 billion	$3.80 billion to $3.90 billion	+$0.05B at low end, +$0.05B at high end; growth rate raised from 13% to 14% at midpoint	Raised
Operating EBITDA Margin Expansion	FY2025	approximately 150 basis points	approximately 165 basis points	+15 basis points	Raised
Net Cost Improvement Target	FY2025	$450 million	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Free Cash Flow (approximately $1.9 billion)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Seed	$0.917B	+32.7%
Crop Protection	$1.701B	+4.0%
Corn Seed Revenue	$586M	—
Soybean Seed Revenue	$152M	—
Herbicides Revenue	$813M	—
Insecticides Revenue	$409M	—
Fungicides Revenue	$222M	—
Biologicals Revenue	$147M	—

Other KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
North America	$0.707B	+15.8%
EMEA	$0.462B	+10.7%
Latin America	$1.161B	+16.8%
Asia Pacific	$0.288B	-8.4%
Operating EBITDA	$49M	—
Organic Sales Growth	11%	—

Management tone

Q1 cautious-on-Brazil → Q2 confident, "H2 de-risked" → Q3 forward-leaning, pre-announces FY26 → next: separation execution.

Management has moved from defensive guidance management to offensive narrative-building over three quarters. Last quarter's tone was about beating the bar set in February; this quarter management is setting new bars for 2026 and 2027 while simultaneously broadening the cost metric in a way that reduces accountability on the specific $450M number they raised just 90 days ago. "It's not that we believe things aren't going well today. They are. It's that we believe things could be even better in the future as two separate companies." The separation rationale has hardened from option to imperative.

The cost narrative has shifted in a way worth flagging. Q2: $400M raised to $450M, framed as bottom-up operational efficiency tracked quarter-by-quarter. Q3: $450M target retired, replaced with "over $600M in controllable benefits" — a category that bundles deflation tailwinds with productivity. "We're now expecting to deliver over 600 million in controllable benefits this year." The bigger number reads as a beat-and-raise; the broader definition makes the H1 2026 reset harder to challenge. Both things can be true.

The crop protection industry call has flipped from defensive to constructive. Q2: pricing "stabilized." Q3: "we are now expecting low single digit growth in the crop protection industry, including high single digit growth in biologicals…we see overall CP market pricing stabilizing in 2026." This is the first time management has called industry growth post-destocking — and it's the foundation for the FY26 EBITDA pre-announce.

The seed innovation model has been reframed from proprietary to collaborative. Q2 introduced out-licensing as a $4B opportunity. Q3 went further: "the market has gradually transitioned away from integrated proprietary models to more open source licensing with collaborations now driving innovation success." For a company built on closed-IP corn and soybean germplasm, this is a meaningful philosophical shift — and aligns with the separation logic that an independent Seed company can partner more freely than a bundled crop-inputs conglomerate.

Royalty neutrality continues to accelerate. Net royalty expense improved ~$90M YTD with the FY25 exit position now ~$120M. The 2030 → 2028 pull-forward set last quarter looks well-supported by this trajectory.

Recurring themes management leaned on this quarter:

controllable cost productivity and deflation benefits driving EBITDA outperformancestrategic separation unlocking value and enabling focused innovation in seed and crop protectionnew product launches and biologicals driving volume growth and premium positioningmargin expansion trajectory toward 24% target by 2027Brazil safrinha strength and North America corn acreage advantagetransition from integrated models to collaborative open-source innovation platforms

Risks management surfaced:

global trade uncertainty and potential tariff impacts on soybean acreage shiftscompetitive pricing dynamics in major crop protection markets, particularly Brazilseparation execution risks and timing to 2H 2026uncontrollable weather and order timing volatility between quarterscurrency headwinds from Brazilian real, Turkish lira, and Canadian dollar

Q&A highlights

Chris Parkinson · Wolf Research

What aspect of Corteva's crop protection business strategy (new actives pipeline, plant health vs biologicals balance, Spinosan franchise positioning) is most missed by the market, and what should differentiate the independent company going forward?

Management emphasized consistent strategy of driving differentiated technology to farmers. Highlighted 200 basis points of margin improvement over 5 years, $9 billion R&D pipeline, and Spinosan reaching ~$900 million revenue. Noted new products (Renscor, RLX, Reclamel) driving landscape. As independent company, expects more doors to open with seed companies, retailers, and co-ops. Committed to 20% EBITDA margins by 2027 with continued R&D at 6-7% of revenue.

Crop protection margins up ~160-200 basis points over 5 yearsSpinosan franchise at ~$900 million revenue this year$9 billion R&D pipeline20% EBITDA margin target for crop protection by 2027

Josh Spector · UBS

Why is Corteva not changing crop chem pricing expectations for H2 vs peers, and what gives confidence in low single-digit 2026 growth forecasting when it's early in the cycle?

Management expects H2 pricing down low single digits overall, with Brazil improving to mid single digits (vs high single digit losses last year). Rest of regions running flat. For 2026, expects global crop protection to return to low single-digit growth driven by volume with pricing stabilizing. Confidence based on strong on-farm applications, healthy channel inventories, stable China generic prices, and volume strength from new acreage in Brazil.

2025 crop chem pricing expected down low single digits overallBrazil pricing H2 2025: mid single digit decline (vs high single digit last year)2026 Brazil pricing expected low single digit decline2025 global crop protection expected flat

David Begleiter · Deutsche Bank

Why are biologicals only growing 7% when they're positioned as a key part of the independent CP story?

Management noted biologicals revenue grew from ~$400 million to ~$600 million, representing strong growth relative to market backdrop. Growth rate explained by: (1) time required to commercialize new products globally, (2) recent North America branded launch showing good farmer adoption, and (3) early-stage progress in Brazil and Europe. Expected continued high single-digit to low double-digit growth going forward.

Biologicals revenue: ~$400 million → ~$600 million7% current growth rateFirst branded North America launch completed this springExpected future growth: high single-digit to low double-digit

Jeff Zekoskis · JP Morgan

How will diamide and insecticide pricing pressures affect Spinosan volume and pricing, and is Spinosan the area of greatest 2025 price pressure concern?

Management acknowledged pricing pressures on insecticide portfolio but noted Spinosan volumes continue growing. Spinosan finishing near $900 million with 5% organic growth in flat market. Emphasized Spinosan as rotation partner for resistance management, differentiating it from commoditized generics. New products (Paraxalt, Reclamel) up 30% combined. Explained Spinosan's microbial nature (not chemical) provides premium because difficult to replicate—has been engineered for ~20 years with proprietary strain.

Spinosan: $900 million revenue, 5% organic growth in flat marketSpinosan is microbial (not chemical), engineered for ~20 yearsNew insecticide products (Paraxalt, Reclamel) up 30% combined YTDSpinosan and diamides are complementary (rotational use)

Duffy Fisher · Goldman Sachs

What market share gains did Corteva achieve in Northern Hemisphere corn, soy, cotton, canola? How fast is Conquesta growing and what is the size opportunity in Brazil?

Management confirmed market share gains in both corn and soy, with larger gains in soy. Held price mainly through mix. On Conquesta: currently 8-10% of Brazil market in 2025, growing to double digits in 2026, potentially one-third of market by 2030 (combined with E3 technology). Product performance confidence high based on germplasm.

Picked up corn market share through product performance and mixPicked up even larger soy market shareHeld price mainly through mix in cornConquesta: 8-10% Brazil market share 2025

Answers to last quarter's watch list

Seed Latin America recovery in Q3/Q4 — Resolved. Latin America revenue +16.8% in Q3 to $1.16B, and Seed +32.7% overall confirms the safrinha demand pull-forward management forecast in August. Brazilian real and trade-route uncertainty remain but did not derail the seasonal ramp. Status: Resolved positively

Crop Protection pricing in Brazil during H2 — Partially resolved. Management now sees H2 2025 Brazil pricing down mid-single-digits (vs. high-single-digit declines last year) and 2026 Brazil pricing down only low-single-digits. CP volume growth continued (segment +4% YoY), keeping the segment positive despite price headwinds. Industry pricing now expected to stabilize globally in 2026. Status: Resolved positively

Cost program execution beyond $450M — The $450M target was withdrawn and replaced with "over $600M in controllable benefits." The new number is bigger but the metric is broader (includes deflation), so direct comparability to the $450M is lost. EBITDA margin expansion expectation went to ~165bps from ~150bps, suggesting genuine outperformance, but the disclosure change makes it harder to track the 2027 $700M cumulative cost framework on the original metric. Status: Not resolved

Out-licensing revenue disclosure — Not addressed in the Q3 print or Q&A material we reviewed. The $4B sizing from Q2 was not refreshed and no specific deal-count or run-rate disclosure was provided. Tone shift toward "open source licensing with collaborations" is directionally supportive but not quantified. Status: Continue monitoring

Q4 working capital and FCF conversion — FCF guidance reaffirmed at ~$1.9B with ~50% cash conversion. No mid-cycle revision suggests crop prepaid deposits are landing as planned, but the Q4 print is still the test. Status: Continue monitoring

What to watch into next quarter

The cost narrative reset. Watch whether the February FY26 guide quantifies the "controllable benefits" framework on a comparable basis to the retired $450M net cost improvement metric — if it doesn't, the disclosure change becomes structural and the 2027 $700M cumulative cost number loses its tracking anchor.

FY26 EBITDA "approximately $4.1B" credibility. Pre-announcing FY26 on a Q3 call locks management in. Watch whether February's formal FY26 guide confirms $4.1B or walks it back, and whether the cost line and CP industry growth assumptions hold up after Q4 close.

FCF print and conversion. $1.9B FCF at ~50% conversion has now been reaffirmed twice. Watch whether the Q4 working-capital build (crop prepaid deposits in Brazil and NA) lands as planned — this is the cleanest read on whether the raised EPS and EBITDA prints are quality earnings.

Biologicals run-rate acceleration. Q3 biologicals revenue of $147M annualizes well below the ~$600M FY figure management cited in Q&A; watch whether Q4 disclosure provides clearer YoY growth in biologicals specifically and whether the NA branded launch shows pull-through into FY26.

Separation timeline and dis-synergy quantification. Targeted for 2H 2026. Watch the February guide for explicit dis-synergy costs and standalone Seed/CP P&L framing — particularly whether the 20% CP EBITDA margin by 2027 is restated as a standalone-company target.

Brazil safrinha Q4 conversion. Q3 strength was partly pulled forward from Q4; watch whether Q4 Seed LatAm growth normalizes or surprises again.

Sources

Corteva Q3 2025 Earnings Schedules, SEC Form 8-K (September 30, 2025 period): https://www.sec.gov/Archives/edgar/data/1755672/000175567225000020/a93025enrschedules.htm
Corteva Q3 2025 earnings call commentary (Chuck Magro, David Johnson) — guidance raise, controllable benefits framing, FY26 pre-announce, and Q&A as cited above.
Tapebrief Q2 2025 CTVA brief — prior guidance baseline and watch list.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.